Last reviewed · How we verify
Ramipril 5 MG
At a glance
| Generic name | Ramipril 5 MG |
|---|---|
| Also known as | ACE inhibitor |
| Sponsor | Ukrainian Medical Stomatological Academy |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing Ramipril to Prevent Memory Loss in People With Glioblastoma (PHASE2)
- Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants (PHASE4)
- Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure (PHASE4)
- Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD） (PHASE4)
- Secondary Prevention of Cardiovascular Disease in the Elderly Trial (PHASE3)
- Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients (PHASE4)
- The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramipril 5 MG CI brief — competitive landscape report
- Ramipril 5 MG updates RSS · CI watch RSS
- Ukrainian Medical Stomatological Academy portfolio CI